• EGOC · OTC
  • DUSS · OTC
  • CGFIA · OTCQB
  • POTG · OTCQB
  • EMXC · OTC
  • TYTN · OTC
  • TDGI · OTC
  • LUXD · OTCQB
  • NYXO · OTCQB
  • LBAS · OTCQB
  • Newsletter Features Explosive Penny Stocks Active On News SMHS, SPBU, SILA, CHTP

    Written by: Dana Salvo

    Bookmark and Share

    SPBU Moving on Newsspbu otcbb

    Sept 20, 2010 Boca Raton, FL– TheStockwizards.net analyzes up-to-the-minute OTC-OTCBB, NYSE, and NASDAQ Small,Micro Cap Penny Stocks like OTCBB SPBU that are active gainers on news. TSW looks for penny stocks like OTCBB SPBU that have active volume & strong momentum, percentage gainers for the mid-morning session The best penny stocks included are: SMHS, SPBU, SILA, CHTP

    Get the Latest Trends and Trading Tips from Veteran Penny Stocks Traders. Tour The TSW Website learn how to take home huge profits trading penny stocks like OTC GLSO.

    Sign Up For Our Red Hot OTC Penny Stock Newsletter put out each weekend as we highlight some of the biggest moving OTCBB Penny Stocks, Small Cap & Micro Cap Stocks like OTCBB SPBU before they start breaking out. The most up-to-date weekend Penny Stocks Newsletter around. For more information on how to find stocks like SPBU , go to Traders Corner.

    (OTC: SMHS — Smart Holdings, Inc.)

    CURRENT NEWS!!

    Smart Holdings Announces Contract with Paylink to Offer Customers Instant Credit and 0% Financing on Its “Best of Class” Product

    MARIETTA, Ga., Sep 20, 2010 — Smart Holdings, Inc. (SMHS.PK), through its wholly owned subsidiary, Assurance Group Direct, today announced that it has signed a deal with Paylink Payment Plans, LLC (“Paylink”), a finance company, to provide consumers with Instant Credit and 0% financing with no credit check; opening the door to sell to the masses nationwide at affordable monthly prices. Through their contract with Automotive Assurance Group (“AAG”), Paylink will provide financing for every customer with no credit check making it easy for millions of consumers to afford an extended service contract.

    Paylink is one of the nation’s top finance companies that specialize in helping consumers purchase extended service contracts for cars, boats, motorcycles, RV’s and more by offering terms. This deal will allow the Company to finance any customer with no credit check right over the phone while the seller in many cases can receive their portion of the sale profits immediately. For more information about Paylink, go to: www.warrantyfinance.com.

    “Auto repairs are on the rise and we believe that 0% financing is one of the keys to building a large volume of sales quickly. With Paylink financing in place, Smart Holdings can offer 0% financing for up to 18 months and every customer qualifies with no credit check, opening the door for millions of consumers who manufacturers’ warranties are expiring every day, plus the 100 million used cars in the market every year. Consumers will get high quality extended coverage all backed by an A-rated insurance company like American Bankers, and administered by NAC, a 26 year old company with a successful track record,” said Nick Damico, President and CEO of Automotive Assurance Group.

    About Smart Holdings, Inc.

    Headquartered in Marietta, GA, Smart Holdings, Inc., through its wholly owned subsidiary, Assurance Group Direct, is in the business of selling automotive extended service plans on a nationwide basis directly to consumers through national television advertising and internet marketing as well as traditional wholesale distribution channels such as the brick and mortar auto dealers, used car dealers, service drives, auctions and through organizations and finance companies.

    For more information, please visit: www.smartholdingsinc.com.

    (OTCBB: SPBU — Spare Backup, Inc.)

    Current News !!

    SPBU Spare Backup and Spare Mobile to Be Bundled in “Geek Squad Max” Computing and “Max Mobile Protection” Programs in U.K.

    PALM DESERT, Calif., Sep 20, 2010 — Spare Backup (OTCBB:SPBU) today announced that the Carphone Warehouse Limited (CPW), a unit of Buy Europe Distributions Limited (BBE), will begin the launch of its Geek Squad Max Computing and Max Mobile protection programs in October 2010. Spare Backup’s Co-branded My-Hub backup and cloud computing services along with Spare Mobile will be bundled in the service programs. spbu

    The initial launch in England will be throughout The CPW’s U.K. locations and online, CPW currently operates within nine countries in Europe. SPBU Spare Backup will provide co-branded storage services included in the bundle to The Geek Squad customers who subscribe to the paid insurance programs. SPBU Spare Backup will receive an undisclosed annual payment from CPW for each Max Computing or Max Mobile subscriber.spbu

    SPBU Spare Backup will be responsible for maintaining the integrity of the data and for the administration and operation of the Backup Website and service delivery. SPBU Spare Backup will ensure that the Backup Website is available on a 24/7 basis except for scheduled maintenance or in the event of an emergency.spbu

    SPBU Spare Backup is the first totally automated online backup service that intelligently selects, secures and stores files without any user intervention.spbu

    “We are excited to be included in the Geek Squad Europe’s Max protection programs as they launch in the U.K. next month. We believe this is a significant milestone for Spare Backup to be automatically included in this point of purchase support program. We look forward to servicing the Geek Squad and its customers as we continue to build a long term partnership.”spbu

    For additional informationon SPBU , visit http://www.sparebackup.com. For investor relations on SPBU , please contact our investor relations department at 760-779-4241 begin_of_the_skype_highlighting              760-779-4241      end_of_the_skype_highlighting Ext. 224 or [email protected] SPBU

    About SPBU Spare Backup, Inc.:

    SPBU Spare Backup, Inc. specializes in helping consumers, small office/home office users and small to mid-sized businesses protect their computer data quickly, automatically and cost-effectively. The company’s flagship Spare Backup product is the first totally automated online backup service that intelligently selects, secures and stores files without any user intervention, automatically backing up documents, email, music, photos and other PC files on a continuous basis or according to the schedule of the user’s choice. SPBU The company is headquartered in Palm Desert, California. spbu

    (OTCBB: SILA —Gold American Mining Corp.)

    Current News !!

    Gold American Mining Corp. Appoints Drilling Contractor for Guadalupe Property

    RENO, NV, Sep 20, 2010  - Gold American Mining Corp. (OTCBB: SILA) (“Gold American” and/or “the Company”) is pleased to announce that Tecmin Servicios S.A. de C.V. has been appointed to carry out the 2010 drilling program at the Guadalupe Property, Zacatecas, Mexico.

    Drilling at Guadalupe is scheduled to begin in the second week of October with a program that is anticipated to total approximately 2,500 meters. The drilling will target the down dip extensions of the more than 6 veins that have been identified on the property to date as well as test two geophysical anomalies identified in the recently completed geophysical survey (see news dated August 30, 2010).

    Workings at the Santa Rosa and San Antonio veins, located in the south of the property, are known to extend at least 270 vertical meters. The drill holes planned will target these vein systems approximately 400 meters below the surface. This will also test a coincident strong Induced Polarization chargeability anomaly that was unknown to the Company prior to optioning the project.

    “The results of our initial work on the Guadalupe property have increased our optimism regarding its potential. We believe that Guadalupe has excellent potential to develop into a top-tier mineral deposit and look forward to initiating drilling operations,” commented Mr. Johannes Petersen, Gold American’s CEO. “We selected Tecmin Servicios to drill Guadalupe for their experience in the area and their outstanding credentials, which include working for a number of important mining companies such as Fresnillo plc,” added Mr. Petersen.

    THE GUADALUPE PROPERTY The Guadalupe property contains two historically significant mines and is located in one of Mexico’s oldest mining districts, roughly 5 miles north of the Fresnillo (Proano) Mine, the world’s richest underground silver mine, operated by Fresnillo plc. Roughly 6.8 miles to the southwest of Silver America’s Guadalupe Property is the Juanicipio Joint Venture (JV) between MAG Silver Corp. (MAG) and Fresnillo plc, which is known as one of the world’s highest grade undeveloped silver resources.

    The Property contains greater than 20 known workings as well as two historic mines — Santa Rita and San Antonio. Historic records containing references to the Santa Rita and San Antonio mines suggest that both mines were important and reached their height of production between 1910 and 1920 but were last in production in the 1980s. The property is completely surrounded by land controlled by Penoles (either through Fresnillo or other subsidiaries and partners).

    Highlight results from previous results include:

    --  1.00 g/t Au and 946.9 g/t Ag over 1.1m (including 1.83 g/t Au and
        1,800.0 g/t Ag over 0.5 m)
    --  0.30 g/t Au and 622.0 g/t Ag from a mineralized dump
    --  0.59 g/t Au and 330.0 g/t Ag over 0.7 m
    --  5.35 g/t Au and 1,189.0 g/t Ag from a mineralized dump

    ABOUT GOLD AMERICAN MINING CORP. Gold American Mining Corp. is a publicly traded (OTCBB: SILA) precious metals exploration company focused on the aggressive, ongoing acquisition and exploration of holdings with rich gold and silver production potential. Based in Reno, Nevada, Gold American has developed a promising portfolio of international properties in regions marked by stable politics, sound economies and friendly business relations. For more information the Company and its projects, visit Gold American’s website at www.gold-american.com.

    ON BEHALF OF THE BOARD OF DIRECTORS,

    Johannes Petersen, President

    (NASDAQ: CHTP — Chelsea Therapeutics International, Ltd.)

    Current News !!

    Chelsea Therapeutics Reports Phase III Trial of Northera Met Primary Endpoint and Achieved Highly Significant Symptomatic Benefits in Neurogenic Orthostatic Hypotension

    CHARLOTTE, N.C., Sept. 20, 2010 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that preliminary analyses of its Phase III NORTHERA(TM) Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement (p=0.003) in symptoms associated with neurogenic orthostatic hypotension (NOH), a chronic and often debilitating drop in blood pressure upon standing. Study results also showed that Northera was both safe and very well tolerated.

    “We are extremely excited by these top-line results which provide validation of the safety and efficacy of Northera as a novel treatment for symptomatic neurogenic orthostatic hypotension, a serious condition for which there is an urgent need for improved treatments,” said Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. “Symptoms of chronic neurogenic orthostatic hypotension are severe, not only putting patients at high risk for falls and associated injuries but also severely impacting their quality of life and generating significant added health care costs. Northera is the first and only drug to repeatedly demonstrate clinical improvement in these patients by both alleviating symptoms of neurogenic orthostatic hypotension and improving their ability to perform daily activities.”

    Northera Trial Meets Primary and Multiple Secondary Endpoints

    Patients randomized into this double-blind, placebo controlled study were evaluated for symptomatic and functional improvement using the orthostatic hypotension questionnaire (OHQ), which is specifically designed to rate the severity of symptoms resulting from low blood pressure and the degree those symptoms interfere with a patient’s ability to perform activities of daily living.

    The OHQ is a two-part questionnaire that uses an 11-point scale (zero to 10) to assess the severity of six symptoms on the orthostatic hypotension symptom assessment scale (OHSA) and four patient function criteria on the orthostatic hypotension daily activities scale (OHDAS). The trial’s primary outcome measure, the composite OHQ score, reflects the average improvement (decrease) in mean OHSA and OHDAS scores.

                                                         Improvement
                                      Change From           Over       Statistical
                                     Randomization         Placebo    Significance
                                -----------------------  -----------  ------------
                                   Placebo     Northera
                                   (N=79*)      (N=81*)     Delta        P-Value
                                -------------  --------  -----------  ------------
      Primary Endpoint:
      ------------------------
       Composite OHQ                    -0.93     -1.83         0.90         0.003
      Secondary Endpoints:
      ------------------------
       OHSA:
         1. Dizziness                   -1.10     -2.40         1.30        <0.001
         2. Vision                      -0.70     -1.60         0.90         0.013
         3. Weakness                    -0.90     -1.90         1.00         0.007
         4. Fatigue                     -1.20     -1.90         0.70         0.030
         5. Concentration               -0.90     -0.90         0.00         0.355
         6. Head & Neck Pain            -0.80     -1.00         0.20         0.975
         Composite OHSA (#1-6)          -0.95     -1.68         0.73         0.010
       OHDAS:
         1. Standing Short
          Time                          -0.80     -1.90         1.10         0.003
         2. Standing Long Time          -1.00     -2.30         1.30         0.001
         3. Walking Short Time          -0.60     -1.70         1.10         0.009
         4. Walking Long Time           -1.10     -1.80         0.70         0.007
         Composite OHDAS
          (#1-4)                        -0.92     -1.98         1.06         0.003
      * modified ITT
       population

    Notably, in addition to the symptomatic and functional benefits registered on the OHQ, an analysis of blood pressure findings validate Northera’s unique mechanism of action and confirmed the preferential effect of Northera on standing systolic blood pressure versus supine systolic blood pressure. Northera demonstrated a statistically significant improvement in standing systolic blood pressure (SBP) (p< 0.001) relative to placebo with Northera patients reporting a mean increase of 11.2 mmHg compared to a mean change of 3.9 mmHg in standing SBP for the placebo group.This significant improvement was achieved with a relatively minor impact on supine blood pressure, with mean standing SBP for patients on Northera increasing 12% compared to only a 6% increase in mean supine SBP. Furthermore, no patients receiving Northera had SBP>200 mmHg during the comparative phase of the trial.

    No Significant Adverse Events

    As anticipated, Northera proved to be safe and well tolerated at all dose levels. Headache (7.4%) was the most common adverse event reported, with all cases considered mild. Consistent with prior study results, treatment with Northera was associated with fewer patient reported falls. In Study 301, all 3 patient-reported falls were in the placebo arm while no patients on Northera arm reported falling during the one-week treatment period.

    Innovative Study of Symptomatic Benefit Conducted Under Special Protocol Assessment

    Study 301 was a randomized, placebo-controlled Phase III trial designed to measure the efficacy of Northera in treating symptoms of neurogenic orthostatic hypotension in patients suffering from primary autonomic failure.

    The study was conducted under a Special Protocol Assessment (SPA) granted by the FDA in February 2008. An SPA provides a binding agreement that the study design, including trial size, clinical endpoints and/or data analyses is acceptable to support regulatory approval. In addition to the SPA for Study 301, the FDA granted Fast Track designation to Chelsea’s pivotal program in NOH. Fast Track designation is designed to facilitate the review of products that address serious or potentially life-threatening conditions for which there is an unmet medical need and provides the option to file a New Drug Application (NDA) on a rolling basis. This permits the FDA to review the filing as it is received, expediting the review process.

    The novel design of this multi-national, placebo-controlled trial consisted of an initial open-label dose titration followed by a 7-day open-label washout period prior to a 7-day double-blind randomized, placebo-controlled treatment period. During the open-label dose titration period, all patients were titrated to an optimal therapeutic dose of Northera, up to 600 mg t.i.d., and were required to demonstrate both a blood pressure and symptomatic improvement to be eligible for the blinded study. Once a patient’s individual optimal therapeutic dose was determined, each patient was taken off drug and washed out for a 7-day period. Patients were then randomized to either placebo (N=79) or Northera treatment (N=81) for one week. At the end of the one-week period, patients were evaluated for changes in symptomatic benefit as measured by the composite OHQ. The modified intent to treat population consisted of 160 patients (65 PD, 25 MSA, 54 PAF, 16 other) enrolled across a total of 65 U.S. and international sites.

    Conference Call Today at 8:30 AM ET

    Chelsea will discuss the Northera Phase III clinical trial results today, September 20, 2010, at 8:30 AM Eastern Time. Interested investors may participate in the conference call by dialing 877-638-9567 begin_of_the_skype_highlighting              877-638-9567      end_of_the_skype_highlighting (domestic) or 720-545-0009 begin_of_the_skype_highlighting              720-545-0009      end_of_the_skype_highlighting (international). A replay will be available for one week following the call by dialing 800-642-1687 begin_of_the_skype_highlighting              800-642-1687      end_of_the_skype_highlighting for domestic participants or 706-645-9291 begin_of_the_skype_highlighting              706-645-9291      end_of_the_skype_highlighting for international participants and entering passcode 12191422 when prompted. Participants may also access both the live and archived webcast of the conference call on Chelsea’s web site at www.chelseatherapeutics.com.

    About Neurogenic Orthostatic Hypotension

    It is estimated that over 100,000 patients in the U.S. suffer from chronic symptomatic NOH, a disorder of the nervous system associated with deficient release of norepinephrine, the neurotransmitter used by sympathetic autonomic nerves to send signals to the blood vessels and the heart. NOH is characterized by low blood pressure, lightheadedness, dizziness, blurred vision and fainting episodes upon standing and is commonly associated with Parkinson’s disease, multiple system atrophy and pure autonomic failure.

    The only FDA-approved treatment for orthostatic hypotension has not been shown effective in alleviating the symptoms of the condition and is limited in its use by a pronounced side-effect profile.

    About Northera(TM)

    Northera (droxidopa), the lead investigational agent in Chelsea Therapeutics’ broad pipeline, is currently in Phase III clinical trials for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure — a group of diseases that includes Parkinson’s disease, multiple system atrophy (MSA) and pure autonomic failure (PAF). Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally. Droxidopa is also being studied for the treatment of fibromyalgia and adult attention deficit disorder in two ongoing phase II trials and completed a phase II in intradialytic hypotension (IDH) study with positive results.

    About Chelsea Therapeutics

    Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea’s most advanced drug candidate, Northera(TM) (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Northera, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

    This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, including clinical trials, risk of regulatory approvals, our reliance on our lead drug candidates droxidopa and CH-4051, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing, reliance on key personnel including specifically Dr. Pedder.

    SOURCE: Chelsea Therapeutics

    By Staff

    CONTACT:          CONTACT:  Chelsea Therapeutics
                      Investor Relations
                      Kathryn McNeil
                      704-973-4231 begin_of_the_skype_highlighting              704-973-4231      end_of_the_skype_highlighting

    About TheStockWizards.net

    The Stock Wizards is a Premiere Penny Stocks Financial Portal & Investor Relations Firm that brings a wealth of trading resources to Small Cap Penny Stocks Investors. We analyze daily market activity on stocks like spbu and provide our members with hot stocks like spbu to watch every day. We follow certain chart patterns and bring you penny stock break out alerts, volume spikes, breaking news, hot stocks to watch like spbu, upward trends, mergers and more…

    SPBU Active on News

    SPBU

    September 20, 2010 @ 3:50 pm Trackback URL Posted in Hot Stocks and tagged with , , , , , , , , , , , , , , , .